Retour
Guangzhou Innogen Pharmaceutical Group Co., Ltd (02591.HK)
Graphique du cours de l'action 02591.HK
INNOGEN-B (02591.HK)
Guangzhou Innogen Pharmaceutical Group Co., Ltd
HK$22.32
-0.79%
$-0.17
Marché fermé: Mar 25, 16:00:00 HKT
Statistiques clés
Clôture préc.
$22.32
Prix d'ouverture
$22.5
Plage de la journée
$21.5 - $23.6
Plage de 52 semaines
$21.36 - $74
Volume
845.2K
Volume moyen
856.3K
Rendement en dividend
--
BPA (TTM)
-0.55
Capitalisation boursière
$9.1B
Qu’est-ce que INNOGEN-B ?
Guangzhou Innogen Pharmaceutical Group Co., Ltd. engages in the production and distribution of pharmaceutical products. The company is headquartered in Guangzhou, Guangdong and currently employs 105 full-time employees. The company went IPO on 2025-08-15. The firm is primarily engaged in the commercialization of innovative, humanized, long-acting glucagon-like peptide-1 (GLP-1) receptor agonist. The firm is dedicated to developing therapies for diabetes and other metabolic diseases. The Company’s core product, Efsubaglutide Alfa (brand name: Diabegone), is used for the treatment of type 2 diabetes (T2D). The Company’s primary pipeline drug candidates include YN014, YN401, YN209, YN203, and YN202. The firm principally conducts its businesses in the domestic market.
Fonctionnalités
Ressources
© 2026 Finture Development Limited. Tous droits réservés.
